For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Yuhan Corporation

USPTO Granted Patents = 93

CIPO Patents = 3

EPO Patents = 34

Trademarks = 6

Forward Citations = 216

Loading Chart...

Loading Chart...

324 inventors (with patents filed for the assignee):

Hyun Ju (15 out of 15 patents)

Moo Young Song (14 out of 14 patents)

Ja-Heouk Khoo (13 out of 13 patents)

4. Tae Dong Han (13 out of 13 patents)

5. Jong Wook Lee (13 out of 14 patents)

6. Hyun Ho Choi (12 out of 71 patents)

7. Su Bin Choi (11 out of 11 patents)

8. Dong-Hoon Kim (10 out of 42 patents)

9. Hee Jae Tak (10 out of 10 patents)

10. Sol Park (10 out of 13 patents)

11. Na Ry Ha (10 out of 10 patents)

12. Young-Ae Yoon (10 out of 10 patents)

13. Eun Kyung Kim (10 out of 12 patents)

14. Mi Kyeong Ju (9 out of 9 patents)

15. Woo-Seob Shin (8 out of 8 patents)

Core Competencies:

Aminopyridine Derivatives

EGFR Inhibitors

Bispecific Antibodies

Triazolone Derivatives

Pyrrolidine Compounds

FGF21 Fusion Proteins

Dual Function Proteins

Heteroaryl Compounds

Protein Kinase Inhibitors

Aminopyrimidine Derivatives

Crystalline Forms

Antigen Binding Proteins

93 patents: Sort by Forward Citations

1. 12428401 - Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same (2025-09-30),

2. RE50528 - Compounds and compositions for modulating EGFR mutant kinase activities (2025-08-12),

3. 12338237 - Derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same (2025-06-24),

4. 12318390 - Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt (2025-06-03),

5. 12258328 - 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors (2025-03-25),

6. 12258327 - 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors (2025-03-25),

7. 12240913 - Anti-HER2/anti-4-1BB bispecific antibody and use thereof (2025-03-04),

8. 12227478 - Processes for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same (2025-02-18),

9. 12187714 - Process for preparing aminopyrimidine derivatives (2025-01-07),

10. 12168690 - Anti-EGFR/anti-4-1BB bispecific antibody (2024-12-17),

11. 12110279 - Triazolones, tetrazolones, and imidazolones, or their salts, and pharmaceutical compositions comprising the same (2024-10-08),

12. 11981659 - Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same (2024-05-14),

13. 11981658 - Substituted aminopyridine compounds as EGFR inhibitors (2024-05-14),

14. 11945798 - Substituted aminopyridine compounds as EGFR inhibitors (2024-04-02),

15. 11919952 - Antigen binding proteins that bind PD-L1 (2024-03-05),

Yuhan Corporation is a leading South Korean healthcare company dedicated to developing and manufacturing innovative pharmaceuticals, consumer healthcare products, and medical devices. With a history spanning over 95 years, Yuhan has established itself as a trusted name in the industry. Committed to improving the well-being and quality of life of people worldwide, the company focuses on research and development, ensuring the highest standards of quality and safety. Yuhan Corporation's diversified portfolio includes prescription drugs, over-the-counter medicines, biologics, nutritional supplements, and more, catering to various therapeutic areas. For more information, please visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

93 Patents

#66 in Seoul

#195 in South Korea

#8,039 in the World

Seoul, South Korea

Yuhan Corporation

Forward Citations = 216

324 inventors:

Hyun Ju (15 out of 15 patents)

Moo Young Song (14 out of 14 patents)

Ja-Heouk Khoo (13 out of 13 patents)

4. Tae Dong Han (13 out of 13 patents)

5. Jong Wook Lee (13 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…